文献速递生殖医学

激素替代治疗周期中冻融囊胚移植日血清孕酮水平的个体内变异性

Intra-individual variability of serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles.
PubMed 文献 · Hum Reprod · 2024-01-01

本研究为观察性队列研究,纳入2019年1月至2020年3月间在本机构大学附属生殖医学中心接受至少两个连续单囊胚激素替代治疗-冻融胚胎移植(HRT-FET)周期的264例患者,比较两次移植日血清孕酮水平。结果显示两次移植日孕酮均值无显著个体内变异(13.4 ± 5.1 ng/ml vs 13.9 ± 5.0 ng/ml,P = 0.08),49例(18.6%)两次测量结果不一致,37例(14.0%)个体内变异高,未发现与高变异或测量不一致相关的临床参数。作者认为首次移植日血清孕酮水平可用于后续周期的个体化黄体期支持。

要点

  • 连续两个HRT-FET周期移植日血清孕酮水平无显著个体内变异(P = 0.08)。
  • 18.6%患者两次孕酮测量结果不一致(一次高于、一次低于9.8 ng/ml阈值)。
  • 14.0%患者个体内变异高(差值大于第75百分位数6.0 ng/ml)。

核心结论

  • 连续两个HRT-FET周期之间血清孕酮水平无显著个体内变异,血清孕酮水平在超过80%的病例中似乎具有可重复性。
  • 作者认为首次移植日测得的血清孕酮水平可用于后续周期的个体化黄体期支持。

研究设计与样本

  • 观察性队列研究,在本机构大学附属生殖医学中心进行。
  • 纳入2019年1月至2020年3月间接受至少两个连续单自体囊胚HRT-FET周期的女性。
  • 共纳入264例患者,平均年龄35.0 ± 4.2岁。
  • 子宫内膜准备采用外源性雌二醇和阴道微粒化孕酮,由单一实验室在冻融胚胎移植日早晨测量血清孕酮。
  • 比较第一次(FET1)和第二次(FET2)移植日两次孕酮测量值,评估个体内变异,酌情进行配对统计分析。

主要发现

  • FET1与FET2之间无显著个体内变异(FET1后平均孕酮水平13.4 ± 5.1 ng/ml vs FET2后13.9 ± 5.0 ng/ml,P = 0.08)。
  • 第一次和第二次FET的胚胎移植特征相似。
  • 49例患者(18.6%)在FET1和FET2之间孕酮水平不一致(定义为一次测量值高于、一次低于9.8 ng/ml阈值)。
  • 37/264例女性(14.0%)在FET1和FET2之间个体内变异高(定义为血清孕酮值差值大于第75百分位数6.0 ng/ml)。
  • 无特定临床参数与高个体内变异或孕酮测量不一致相关。

关键数值与推荐

  • 血清孕酮阈值9.8 ng/ml为团队既往研究中发现的与单自体囊胚HRT-FET活产率显著相关的阈值。
  • 孕酮测量不一致定义为一次测量值高于、一次低于9.8 ng/ml阈值。
  • 高个体内变异定义为血清孕酮值差值大于第75百分位数6.0 ng/ml。

临床怎么用

  • 作者认为首次移植日测得的血清孕酮水平可用于后续周期的个体化黄体期支持。
  • 原文未据此给出推荐。

局限性

  • 本研究受其回顾性设计限制。
  • 仅纳入采用阴道微粒化孕酮进行自体囊胚HRT-FET的女性,限制了研究结果外推至其他孕酮给药途径和其他FET子宫内膜准备方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there a significant intra-individual variability of serum progesterone levels on the day of single blastocyst Hormone Replacement Therapy-Frozen Embryo Transfer (HRT-FET) between two consecutive cycles? SUMMARY ANSWER: No significant intra-individual variability of serum progesterone (P) levels was noted between two consecutive HRT-FET cycles. WHAT IS KNOWN ALREADY: In HRT-FET cycles, a minimum P level on the day of embryo transfer is necessary to optimise reproductive outcomes. In a previous study by our team, a threshold of 9.8 ng/ml serum P was identified as significantly associated with the live birth rates in single autologous blastocyst transfers under HRT using micronized vaginal progesterone (MVP). Such patients may benefit from an intensive luteal phase support (LPS) using other routes of P administration in addition to MVP. A crucial question in the way towards individualising LPS is whether serum P measurements are reproducible for a given patient in consecutive HRT-FET cycles, using the same LPS. STUDY DESIGN, SIZE, DURATION: We conducted an observational cohort study at the university-based reproductive medicine centre of our institution focusing on women who underwent at least two consecutive single autologous blastocyst HRT-FET cycles between January 2019 and March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients undergoing two consecutive single autologous blastocyst HRT-FET cycles using exogenous oestradiol and vaginal micronized progesterone for endometrial preparation were included. Serum progesterone levels were measured on the morning of the Frozen Embryo Transfer (FET), by a single laboratory. The two measurements of progesterone levels performed on the day of the first (FET1) and the second FET (FET2) were compared to evaluate the intra-individual variability of serum P levels. Paired statistical analyses were performed, as appropriate. MAIN RESULTS AND THE ROLE OF CHANCE: Two hundred and sixty-four patients undergoing two consecutive single autologous blastocyst HRT-FET were included. The mean age of the included women was 35.0 ± 4.2 years. No significant intra-individual variability was observed between FET1 and FET2 (mean progesterone level after FET1: 13.4 ± 5.1 ng/ml vs after FET2: 13.9 ± 5.0; P = 0.08). The characteristics of the embryo transfers were similar between the first and the second FET. Forty-nine patients (18.6%) had discordant progesterone levels (defined as one progesterone measurement > and one ≤ to the threshold of 9.8 ng/ml) between FET1 and FET2. There were 37/264 women (14.0%) who had high intra-individual variability (defined as a difference in serum progesterone values >75th percentile (6.0 ng/ml)) between FET1 and FET2. No specific clinical parameter was associated with a high intra-individual variability nor a discordant P measurement. LIMITATIONS, REASONS FOR CAUTION: This study is limited by its retrospective design. Moreover, only women undergoing autologous blastocyst HRT-FET with MVP were included, thereby limiting the extrapolation of the study findings to other routes of P administration and other kinds of endometrial preparation for FET. WIDER IMPLICATIONS OF THE FINDINGS: No significant intra-individual variability was noted. The serum progesterone level appeared to be reproducible in >80% of cases. These findings suggest that the serum progesterone level measured on the day of the first transfer can be used to individualize luteal phase support in subsequent cycles. STUDY FUNDING/COMPETING INTEREST(S): No funding or competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bourdon M, Guihard C, Maignien C, et al. Intra-individual variability of serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles. Hum Reprod. 2024. PMID: 38332539. doi:10.1093/humrep/deae015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。